iMAb – MedXcell collaboration

iMAb and MedXcell partner to develop a novel cell immunotherapy strategy against cancer

Latest news

June 22, 2026

Mabqi selected to join the PSCC BOOST Programme

May 29, 2026

Join Mabqi’s team at the 14th Antibody Industrial Symposium in Montpellier !

May 21, 2026

Join Mabqi at BIO International Convention 2026 in San Diego !

April 28, 2026

Join Mabqi at the Antibody Engineering & Therapeutics 2026 in Basel

Mabqi is a biotechnology company focused on the discovery and development of fully human antibodies. Leveraging its LiteMab© Antibody Discovery Studio, the company specializes in discovering monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), pH-sensitive antibodies, and other innovative formats such as bispecifics, multispecifics, TCE.

Subscribe to our newsletter

Legal notice